German Health Insurers Slash Osteopathy Reimbursement After Evidence Review Finds No Benefit for Back Pain
Published on 06/18/2026 at 13:04 | Redaktion boerse-global.de
Eight in ten Germans will experience non-specific back pain at some point in their lives, yet for roughly nine out of ten cases, doctors never identify a clear cause. Despite the soaring popularity of osteopathic treatment, a new evidence report from the Medical Service of the Federal (Medizinischer Dienst des Bundes) has cast doubt on whether it actually works.
The report, which analyzed clinical trials on osteopathy for low back pain, found no clear benefit over placebo. Some of the largest studies reviewed showed no significant advantage when patients received genuine osteopathic manipulation rather than a sham procedure. Experts point to methodological weaknesses in many of the trials and suspect a publication bias – studies with positive findings are more likely to be published, skewing the overall picture.
Professor Daniel Belavy from the University of Applied Sciences in Bochum (Hochschule Bochum) is blunt: "Based on the current evidence, osteopathy is no more effective than a placebo. Health insurers should not be funding these treatments." A more cautious view comes from David Hohenschurz-Schmidt at Imperial College London. "An absence of evidence is not evidence of absence," he says. "We simply don't know whether it works or not – the evidence base is unclear."
A major complicating factor is Germany’s lack of regulation for the profession. The country has no state-mandated training standard for osteopaths and no uniform code of practice. That makes quality control extremely difficult, especially when a single session costs between 80 and 150 euros.
Lucia Gassner of the Austrian Institute for Health Technology Assessment sums up the dilemma: "There is an evidence gap, not a negative verdict on the method as such. And no specific safety risks have been identified."
The financial implications are mounting fast. Many statutory health insurers have long offered osteopathy subsidies as a voluntary extra benefit, but growing budget shortfalls are forcing cuts. The Innovationskasse IKK has already scrapped its osteopathy top-up, which previously covered up to 120 euros per year, along with professional teeth cleaning and travel vaccinations. Federal Health Minister Karl Lauterbach has guaranteed that mandatory benefits will remain untouched, but there is little room left for optional extras.
The new report is likely to accelerate the trend. Insurers facing shrinking margins are under pressure to stop paying for treatments that lack proven effectiveness. And since back pain continues to top the charts for sick days taken in Germany, the search for evidence-based, cost-efficient therapies remains a pressing challenge for the healthcare system.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
